The Peter Cowen-coached Victor Perez makes a rare performance on the DP World Tour
sports1 hour ago
Two Covid-19 antibody therapies are no longer recommended by the World Health Organization (WHO), because the Omicron variant, and its latest offshoots, have likely rendered them obsolete.
The two therapies — which are designed to work by binding to the spike protein of SARS-CoV-2, in order to neutralise the virus' ability to infect cells — were some of the first medicines developed early on in the pandemic.
The virus has since evolved, and mounting evidence from lab tests suggests that the two therapies — sotrovimab, as well as casirivimab-imdevimab — have limited clinical activity against the latest iterations of the virus. As a result, they have also fallen out of favour with the US health regulator.
On Thursday, WHO experts said they strongly advised against the use of the two therapies in patients with Covid-19, reversing previous conditional recommendations endorsing them, as part of a suite of recommendations published in the British Medical Journal.
GSK and partner Vir Biotechnology's sotrovimab — which has generated billions in sales and became one of the British drugmaker's top sellers last year — was pulled off the US market by the US Food and Drug Administration (FDA) in April.
Given the United States had begun to question sotrovimab's clinical effectiveness against Omicron as early as February, the WHO's realisation is coming a little late, said Penny Ward, a visiting professor in pharmaceutical medicine at King's College London.
"Now WHO has issued this recommendation, it will be interesting to see how many other countries align with it," she said.
Regeneron and partner Roche's antibody cocktail casirivimab-imdevimab has also generated billions in sales, and was one of the US drugmaker's top sellers last year.
Back in January, the FDA revised its stance on the treatment, limiting its use to a smaller group of patients, citing its diminished potency against the Omicron variant.
Both therapies continue to be recommended for use by the European drugs regulator.
Another Covid therapy that emerged early in pandemic was Gilead's antiviral remdesivir. The WHO expanded its conditional recommendation for the drug, advising that it could be used in patients with severe Covid, as well as non-severe Covid patients at the highest risk of hospitalisation.
There are a handful of existing Covid therapies that remain useful in the fight against the virus, and others in development that are expected to also benefit patients.
ALSO READ:
The Peter Cowen-coached Victor Perez makes a rare performance on the DP World Tour
sports1 hour ago
Spaniard full of praise for the country: 'I love its culture and transformation into one of the most innovative nations over the past 50 years’
sports1 hour ago
A UAE resident for 46 years, Shaheen celebrates the nation’s growth in sports and development"
sports1 hour ago
The total value of the seized goods was Rs51.6 million
asia1 hour ago
The fiercely competitive event featured 27 Emirates PGA pros battling for the title
sports1 hour ago
Villa's winless streak in all competitions led to them crashing out of the League Cup and dropping to eighth in the Premier League standings
football1 hour ago
Pakistan needed 18.2 overs to score 148-0 and ensure victory after Zimbabwe
cricket2 hours ago
The PCB has already rejected proposals that would allow India to play in a neutral third country, insisting the full schedule from February 19 to March 9 must be staged on their turf
cricket2 hours ago